Safetek -- SFIN -- Announces New Director/CEO

        Print
| Source: Safetek International Inc.

NEW YORK, May 23, 2005 (PRIMEZONE) -- On April 19, 2005, the Company announced the election of Dr. Shay Goldstein as new Director and CEO of Safetek International (Pink Sheets:SFIN). Dr. Goldstein brings to Safetek in-depth medical scientific understanding as well as his experience in developing business strategy and managing growing companies. He has held a variety of business development and operational executive positions with numerous biomedical companies. Prior to joining Safetek, Dr. Goldstein spent 3 years in Silicon Valley, California, as the director of Rimed, Ltd., an Israeli based medical devise company specializing in development of advanced Neuro-diagnostic medical equipment. He established the marketing and sales infrastructure of that company in the U.S. and was responsible for growing the market share from 0% to 14% in the first year of operation. During that period Dr. Goldstein also served as a Life Science Consultant for Silicon Ventures. As an advisor to one of the largest organized groups of Angel Investors in the United States, he provided clinical and business analysis for several medical device and biotechnology projects. Prior to that Dr. Goldstein served 2 years as the business development and medical marketing director at Medidactic, Ltd, both in the U.S. and in Israel. At Medidactic, he managed marketing and sales training projects for several leading healthcare companies internationally, including: "Teva" (Israel), "Roche" (Israel), "Taro" (Israel), "Advanced Stent Technologies (USA) and "Corgentech" (USA). Earlier in his career, Dr. Goldstein was a Co-Founder and Manager of a biotechnology Incubator project that developed a biochemical delivery system for treating Neurodegenerative diseases. Dr. Goldstein received his MD and B.Sc in Medical sciences (Cum Laude) degrees from the Technion, Israel Institute of Technology.

About Safetek

Safetek Inc. intends to focus on development of new therapeutic compounds and/or medical devices through in house development teams and sublicense research facilities. Safetek has also established an Israeli subsidiary to identify and further develop innovative technologies available in that region. Safetek plans to leverage these technologies to create an integrated therapeutic life science company.

Safetek Inc.
Shay Goldstein
Telephone / Fax :+972-3-5463251
Email: